Topical antibiotic approved for treatment of impetigo

Article

The FDA approved retapamulin ointment (Altabax) for the topical treatment of impetigo. Retapamulin is a new molecular entity, which is indicated for use in patients ages 9 months and older [more].

The FDA approved retapamulin ointment (Altabax) for the topical treatment of impetigo. Retapamulin is a new molecular entity, which is indicated for use in patients ages 9 months and older [more].

The safety database contained approximately 2,000 Altabax-treated adults and children aged 9 months and older, and about 1,000 similar patients who received other antibiotics or placebo. The most common reported adverse effect was irritation at the application site.

The FDA encourages physicians to only use this prescription product to treat or prevent infections that are proven or strongly suspected to be caused by the bacterial form of impetigo. This will reduce the chance of drug-resistant bacteria to Altabax and other antibacterial medications.

Newsletter

Access practical, evidence-based guidance to support better care for our youngest patients. Join our email list for the latest clinical updates.

Recent Videos
John Browning, MD, provides practical skincare reminders ahead of summer season
Potential downstream benefits of RSV preventive measures, with Octavio Ramilo, MD
Discussing phase 3 data of Panzyga for PANS, with Michael Daines, MD
Contemporary Pediatrics: RX Review: Updates and Unmet Need in RSV thumbnail
Contemporary Pediatrics: RX Review: Updates and Unmet Need in RSV thumbnail
Contemporary Pediatrics: RX Review: Updates and Unmet Need in RSV thumbnail
Staphylococcus aureus risk in infants and neonatologist considerations with Aaron Milstone, MD
© 2025 MJH Life Sciences

All rights reserved.